Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4'-(9-acridinylamino)methanesulfon-m-anisidide combilexin

Molecular Pharmacology

Volumn 51, Issue 3, 1997, Pages 448-461

  Henichart, Jean Pierre ^a   Waring, Michael J ^b   Riou, Jean Francois ^c   Denny, William A ^d   Bailly, Christian ^e  

^a Universite de Lille   (France)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c SANOFI   (France)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e Institut de Recherche sur le Cancer de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; AMSACRINE; BENZOTRIAZOLE DERIVATIVE; CAMPTOTHECIN; COMBILEXIN; CONGOCIDINE; COPPER; CYTIDINE; DEOXYRIBONUCLEASE I; DICYCLOHEXYLCARBODIIMIDE; DNA FRAGMENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GUANOSINE; INTERCALATING AGENT; LUCIGENIN; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; SN 16713; UNCLASSIFIED DRUG;

ARTICLE; AUTOOXIDATION; BASE PAIRING; CHEMOLUMINESCENCE; DNA CLEAVAGE; DNA DRUG COMPLEX; DNA FOOTPRINTING; DRUG MIXTURE; DRUG OXIDATION; DRUG POTENCY; DRUG SYNTHESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 0030996693     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. 2-actinomycin D complexes and its host DNA. J. Am. Chem. Soc. 116:4154-4165 (1994).
2. Frederick, C. A., L. D. Williams, G. Ughetto, G. A. van der Marel, J. H. van Boom, A. Rich, and A. H.-J. Wang. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 29: 2538-2549 (1990).
3. Chaires, J. B., J. E. Herrera, and M. J. Waring. Preferential binding of daunomycin to 5′(A/T)CG and 5′(A/T)GC sequences revealed by footprinting titration experiments. Biochemistry 29:6145-6153 (1990).
4. Bailly, C., G. Ridge, D. E. Graves, and M. J. Waring. Use of a photoactive derivative of actinomycin D to investigate shuffling between binding sites on DNA. Biochemistry 33:8736-8745 (1994).
5. Waring, M. J. Echinomycin and related quinoxaline antibiotics, in Molecular Aspects of Anticancer Drug-DNA Interactions (S. Neidle and M. J. Waring, eds.). Vol 1. Macmillan, Basingstoke/London, 213-242 (1993).
6. Gao, X., A. Stassinopoulos, J. S. Rice, and I. H. Goldberg. Structural basis for the sequence-specific DNA strand cleavage by the enedyine neocarzinostatin chromophore: structure of the post-activated chromophore-DNA complex. Biochemistry 34:40-49 (1995).
7. Bailly, C., and J. P. Hénichart. Molecular pharmacology of intercalator-minor groove binder hybrid groove binder hybrid molecules, in Molecular Aspects of Anticancer Drug-DNA Interactions (S. Neidle and M. J. Waring, eds.). Vol. 2. Macmillan, London, 162-196 (1994).
8. Cassileth, P. A., and R. P. Gale. Amsacrine: a review. Leukemia Res. 10:1257-1265 (1986).
9. Ralph, R. K., W. Judd, Y. Pommier, and K. W. Kohn. DNA topoisomerases, in Molecular Aspects of Anticancer Drug-DNA Interactions (S. Neidle and M. J. Waring, eds.). Vol. 2. Macmillan, London, 1-95 (1993).
10. Bailly, C., C. Michaux, P. Colson, C. Houssier, J. S. Sun, T. Garestier, C. Hélène, J. P. Hénichart, C. Rivalle, E. Bisagni, and M. J. Waring. Reaction of a biscationic distamycin-ellipticine hybrid ligand with DNA: mode and sequence specificity of binding. Biochemistry 33:15348-15364 (1994).
11. Bailly, C., M. Collyn-d'Hooghe, D. Lantoine, C. Fournier, B. Hecquet, P. Fossé, J. M. Saucier, P. Colson, C. Houssier, and J. P. Hénichart. Biological activity and molecular interaction of a netropsin-acridine hybrid ligand with chromatin and topoisomerase II. Biochem. Pharmacol. 43:457-466 (1992).
12. Bailly, C., W. A. Denny, L. Mellor, L. P. G. Wakelin, and M. J. Waring. Sequence-specificity of the binding of 9-aminoacridine-and amsacrine-4-carboxamides to DNA studied by DNase I footprinting. Biochemistry 31: 3514-3524 (1992).
13. Bourdouxhe-Housiaux, C., P. Colson, C. Houssier, M. J. Waring, and C. Bailly. Interaction of a DNA-threading netropsin-amsacrine combilexin with DNA and chromatin. Biochemistry 35:4251-4264 (1996).
14. van Houte, L. P. A., C. J. van Garderen, and D. J. Patel. The antitumor drug nogalamycin forms two different intercalation complexes with d(GCGT)•d(ACGC). Biochemistry 32:1667-1674 (1993).
15. Hansen, M. R., and L. Hurley. Pluramycins. Old drugs having modern friends in structural biology. Acc. Chem. Res. 29:249-258 (1996).
16. Shoemaker, D. D., R. L. Cysyk, S. Padmanabhan, H. B. Bhat, and L. Malspeis. Identification of the principal biliary metabolite of 4′-(9-acridinylamino)methanesulfon-m-anisidide in rats. Drug Metab. Dispos. 10:35-39 (1982).
17. Kettle, A. J., I. G. C. Robertson, B. D. Palmer, R. F. Anderson, K. B. Patel, and C. C. Winterbourn. Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase. Biochem. Pharmacol. 44:1731-1738 (1992).
18. Wong, A., C.-H. Huang, and S. T. Crooke. Deoxyribonucleic acid breaks produced by 4′-(9-acridinylamino)methanesulfon-m-anisidide and copper. Biochemistry 23:2939-2945 (1984).
19. Wong, A., C.-H. Huang, and S. T. Crooke. Mechanism of deoxyribonucleic acid breakage induced by 4′-(9-acridinylamino)methanesulfon-m-anisidide and copper: role for cuprous ion and oxygen free radicals. Biochemistry 23:2946-2952 (1984).
20. 4′-(9-acridinyl)-3′-methoxy-2′:5′- cyclohexadiene-1′,4′-diimine (m-AQDI), the primary oxidative metabolite of amsacrine, in transformed Chinese hamster fibroblast. Biochem. Pharmacol. 39:1411-1421 (1990).
21. Covey, J. M., K. W. Kohn, D. Kerrigan, E. J. Tilchen, and Y. Pommier. Topoisomerase II-mediated DNA damage produced by 4′-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res. 48:860-865 (1988).
22. Gorsky, L. D., and M. J. Morin. Microsomal activation and increased production of 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide (m-AMSA)-dependent, topoisomerase-associated DNA lesions in nuclei from human HL-60 leukemia cells. Biochem. Pharmacol. 39:1481-1484 (1990).
23. Wakelin, L. P. G., P. Chetcuti, and W. A. Denny. Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix. J. Med. Chem. 33:2039-2044 (1990).
24. Houssin, R., J. L. Bernier, J. P. Hénichart. A convenient and general method for the preparation of tert-butoxycarbonylaminoalkanenitriles and their conversion to mono-tert-butoxycarbonylalkanediamines. Synthesis 3:259-261 (1988)
25. Bailly, C., N. Pommery, R. Houssin, and J. P. Hénichart. Design, synthesis, DNA-binding, and biological activity of a series of DNA minor groove binding intercalating drugs. J. Pharm. Sci. 78:910-917 (1989).
26. Allen, R. C. Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 133:449-493 (1986).
27. Bailly, C., and M. J. Waring. Comparison of different footprinting methodologies for detecting binding sites for a small ligand on DNA. J. Biomol. Struct. Dyn. 12:869-898 (1995).
28. Pommier, Y., G. Capranico, A. Orr, and K. W., Kohn. Distribution of topoisomerase II cleavage sites in Simian virus 40 DNA and the effects of drugs. J. Mol. Biol. 222:909-924 (1991).
29. Marchand, C., C. Bailly, C. H. Nguyen, E. Bisagni, T. Garestier, C. Hélène, and M. J. Waring. Stabilization of triple helical DNA by a benzopyridoquinoxaline intercalator. Biochemistry 35:5022-5032 (1996).
30. Chen, A. Y., C. Yu, B. Gatto, and L. F. Liu. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA 90:8131-8135 (1993).
31. René, B., P. Fossé, T. Khélifa, A. Jacquemin-Sablin, and C. Bailly. The 1′-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Mol. Pharmacol. 49:343-350 (1996).
32. Subra, F., S. Carteau, J. Pager, J. Paoletti, C. Paoletti, C. Auclair, D. Mrani, G. Gosselin, and J. L. Imbach. Bis(pyrrolecarboxamide) linked to intercalating chromophore oxazolopyridocarbazole (OPC): selective binding to DNA and polynucleotides. Biochemistry 30:1642-1650 (1991).
33. Berger, J. M., S. J. Gamblin, S. C. Harrison, and J. C. Wang. Structure and mechanism of DNA topoisomerase II. Nature (Lond.) 379:225-232 (1996).
34. Capranico, G., K. W. Kohn, and Y. Pommier. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 18:6611-6619 (1990).
35. Pommier, Y., G. Capranico, A. Orr, and K. W. Kohn. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in presence of amsacrine or teniposide. Nucleic Acids Res. 19:5973-5980 (1991).
36. Huff, A. C., R. G. Robinson, A. C. Evans, K. N. Selander, M. P. Wentland, J. B. Rake, and S. A. Coughlin. DNA sequence preference at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives. Anti-Cancer Drug Des. 10:251-276 (1995).
37. Howard, M. T., M. P. Lee, T. Hsieh, and J. D. Griffith. Drosophila topoisomerase II-DNA interactions are affected by DNA structure. J. Mol. Biol. 217:53-62 (1992).
38. Udvardy, A., and P. Schedl. Chromatin structure, not DNA sequence specificity, is the primary determinant of topoisomerase II sites of action in vivo. Mol. Cell. Biol. 11:4973-4984 (1991).
39. Borgnetto, M. E., F. Zunino, S. Tinelli, E. Käs, and G. Capranico. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility. Cancer Res. 56:1855-1862 (1996).